NO313935B1 - Anvendelse av angiotensin II antagonister for fremstilling av et medikamentfor behandling av svekket nerveledningshastighet, s¶rligdiabetisk nevropati - Google Patents
Anvendelse av angiotensin II antagonister for fremstilling av et medikamentfor behandling av svekket nerveledningshastighet, s¶rligdiabetisk nevropati Download PDFInfo
- Publication number
- NO313935B1 NO313935B1 NO19943846A NO943846A NO313935B1 NO 313935 B1 NO313935 B1 NO 313935B1 NO 19943846 A NO19943846 A NO 19943846A NO 943846 A NO943846 A NO 943846A NO 313935 B1 NO313935 B1 NO 313935B1
- Authority
- NO
- Norway
- Prior art keywords
- tetrazol
- biphenyl
- conduction velocity
- methyl
- nerve conduction
- Prior art date
Links
- 230000001771 impaired effect Effects 0.000 title claims abstract description 12
- 229940123413 Angiotensin II antagonist Drugs 0.000 title claims abstract description 6
- 208000032131 Diabetic Neuropathies Diseases 0.000 title claims abstract description 6
- 239000002333 angiotensin II receptor antagonist Substances 0.000 title claims abstract description 6
- 230000007830 nerve conduction Effects 0.000 title claims description 19
- 239000003814 drug Substances 0.000 title claims description 11
- 229940079593 drug Drugs 0.000 title claims description 7
- 239000005557 antagonist Substances 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 6
- -1 2'-(1H-tetrazol-5-yl)biphenyl-4-yl Chemical group 0.000 claims description 5
- 230000002969 morbid Effects 0.000 claims description 5
- AWZMTWHHQXOWQR-UHFFFAOYSA-N 2-ethyl-4-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methoxy]-5,6,7,8-tetrahydroquinoline Chemical compound C=12CCCCC2=NC(CC)=CC=1OCC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 AWZMTWHHQXOWQR-UHFFFAOYSA-N 0.000 claims description 3
- FSJCYXPMWQPVOS-UHFFFAOYSA-N 2-ethyl-4-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methoxy]quinoline Chemical compound C=12C=CC=CC2=NC(CC)=CC=1OCC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 FSJCYXPMWQPVOS-UHFFFAOYSA-N 0.000 claims description 3
- PSIFNNKUMBGKDQ-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 PSIFNNKUMBGKDQ-UHFFFAOYSA-N 0.000 claims description 3
- XOJFGOXJJNGYHP-UHFFFAOYSA-N 2-butyl-5-methyl-3-[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]imidazo[4,5-b]pyridine Chemical compound CCCCC1=NC2=CC=C(C)N=C2N1C(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 XOJFGOXJJNGYHP-UHFFFAOYSA-N 0.000 claims description 2
- ABWBGQRWTFBXJA-UHFFFAOYSA-N 2-ethyl-5,6,7-trimethyl-3-[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]imidazo[4,5-b]pyridine Chemical compound CCC1=NC2=C(C)C(C)=C(C)N=C2N1C(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 ABWBGQRWTFBXJA-UHFFFAOYSA-N 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000001537 neural effect Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 3
- BFVNEYDCFJNLGN-UHFFFAOYSA-N 5,7-diethyl-1-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-3,4-dihydro-1,6-naphthyridin-2-one Chemical compound O=C1CCC=2C(CC)=NC(CC)=CC=2N1CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 BFVNEYDCFJNLGN-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- LFEFVHFVYIXKME-UHFFFAOYSA-N 5,7-diethyl-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]-1,6-naphthyridin-2-one Chemical compound O=C1C=CC=2C(CC)=NC(CC)=CC=2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 LFEFVHFVYIXKME-UHFFFAOYSA-N 0.000 description 1
- 208000003130 Alcoholic Neuropathy Diseases 0.000 description 1
- 229940118148 Aldose reductase inhibitor Drugs 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 206010067722 Toxic neuropathy Diseases 0.000 description 1
- 210000000588 acetabulum Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 208000020701 alcoholic polyneuropathy Diseases 0.000 description 1
- 239000003288 aldose reductase inhibitor Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000019382 nerve compression syndrome Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929208116A GB9208116D0 (en) | 1992-04-13 | 1992-04-13 | Therapeutic agents |
| GB929211289A GB9211289D0 (en) | 1992-05-28 | 1992-05-28 | Heterocyclic therapeutic agents |
| PCT/GB1993/000732 WO1993020816A1 (en) | 1992-04-13 | 1993-04-07 | Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO943846D0 NO943846D0 (no) | 1994-10-12 |
| NO943846L NO943846L (no) | 1994-10-12 |
| NO313935B1 true NO313935B1 (no) | 2002-12-30 |
Family
ID=26300705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19943846A NO313935B1 (no) | 1992-04-13 | 1994-10-12 | Anvendelse av angiotensin II antagonister for fremstilling av et medikamentfor behandling av svekket nerveledningshastighet, s¶rligdiabetisk nevropati |
Country Status (14)
| Country | Link |
|---|---|
| EP (2) | EP0872235A1 (https=) |
| JP (1) | JPH07505646A (https=) |
| KR (1) | KR100292396B1 (https=) |
| AT (1) | ATE181830T1 (https=) |
| AU (1) | AU675935B2 (https=) |
| CA (1) | CA2132544C (https=) |
| DE (1) | DE69325574T2 (https=) |
| DK (1) | DK0636027T3 (https=) |
| ES (1) | ES2135472T3 (https=) |
| GR (1) | GR3031261T3 (https=) |
| HU (1) | HUT71331A (https=) |
| NO (1) | NO313935B1 (https=) |
| NZ (1) | NZ251741A (https=) |
| WO (1) | WO1993020816A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7213296A (en) * | 1995-10-06 | 1997-04-30 | Ciba-Geigy Ag | At1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys |
| WO1997031634A1 (en) | 1996-02-29 | 1997-09-04 | Novartis Ag | At1 receptor antagonist for the stimulation of apoptosis |
| PL189066B1 (pl) * | 1996-04-05 | 2005-06-30 | Takeda Pharmaceutical | Kompozycja farmaceutyczna do zapobiegania lub zwalczania chorób związanych z angiotensyną II oraz stosowanie związków do wytwarzania leku do zapobiegania lub zwalczania chorób związanych z angiotensyną II |
| US6465502B1 (en) | 1998-12-23 | 2002-10-15 | Novartis Ag | Additional therapeutic use |
| ATE524176T1 (de) | 1998-12-23 | 2011-09-15 | Novartis Pharma Gmbh | Valsartan tablette |
| CN101011390A (zh) | 1999-01-26 | 2007-08-08 | 诺瓦提斯公司 | 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用 |
| GB0001662D0 (en) | 1999-02-06 | 2000-03-15 | Zeneca Ltd | Pharmaceutical compositions |
| US6211217B1 (en) | 1999-03-16 | 2001-04-03 | Novartis Ag | Method for reducing pericardial fibrosis and adhesion formation |
| DE10335027A1 (de) | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
| PT1830869E (pt) | 2004-12-24 | 2013-08-22 | Spinifex Pharm Pty Ltd | Método de tratamento ou profilaxia |
| US20130131007A1 (en) | 2005-09-07 | 2013-05-23 | Bebaas, Inc. | Vitamin b12 compositions |
| CA2646379C (en) | 2006-03-20 | 2014-12-23 | The University Of Queensland | Method of treatment or prophylaxis inflammatory pain |
| EP1908469A1 (en) | 2006-10-06 | 2008-04-09 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin II receptor antagonist for the treatment of systemic diseases in cats |
| US9095587B2 (en) | 2010-01-19 | 2015-08-04 | Spinifex Pharmaceuticals Pty Ltd | Methods and compositions for improved nerve conduction velocity |
| DK3648761T3 (da) | 2017-07-07 | 2024-06-24 | Boehringer Ingelheim Vetmedica Gmbh | Telmisartan til forebyggelsen eller behandlingen af hypertension i katte |
| MX2022000426A (es) | 2019-07-09 | 2022-04-25 | Boehringer Ingelheim Vetmedica Gmbh | Telmisartan para el tratamiento de la hipertension en perros. |
| CN121175053A (zh) | 2023-05-24 | 2025-12-19 | 勃林格殷格翰动物保健有限公司 | 包含一或多种sglt-2抑制剂及替米沙坦的非人类哺乳动物中肾脏疾病和/或高血压的组合治疗和/或预防 |
| TW202541793A (zh) | 2023-12-15 | 2025-11-01 | 德商百靈佳殷格翰維美迪加股份有限公司 | 用於預防貓之全身性疾病之血管緊張素ii受體拮抗劑 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUT54991A (en) * | 1989-08-11 | 1991-04-29 | Ici Plc | Process for producing quinoline derivatives and pharmaceutical compositions comprising such compounds |
| GB8927277D0 (en) * | 1989-12-01 | 1990-01-31 | Glaxo Group Ltd | Chemical compounds |
| US5140037A (en) * | 1990-03-20 | 1992-08-18 | E. I. Du Pont De Nemours And Company | Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists |
| US5049565A (en) * | 1990-12-07 | 1991-09-17 | Merck & Co., Inc. | Microbial transformation process for preparing anti-hypertensive products |
| GB9027210D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
| GB9027211D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
| IL101860A0 (en) * | 1991-05-31 | 1992-12-30 | Ici Plc | Heterocyclic derivatives |
| ATE152718T1 (de) * | 1991-08-15 | 1997-05-15 | Ciba Geigy Ag | N-acyl-n-heterocyclyl- oder naphthylalkyl- aminosäuren als angiotensin ii antagonisten |
-
1993
- 1993-04-07 NZ NZ251741A patent/NZ251741A/en not_active IP Right Cessation
- 1993-04-07 ES ES93909041T patent/ES2135472T3/es not_active Expired - Lifetime
- 1993-04-07 EP EP98108683A patent/EP0872235A1/en not_active Withdrawn
- 1993-04-07 EP EP93909041A patent/EP0636027B1/en not_active Expired - Lifetime
- 1993-04-07 DK DK93909041T patent/DK0636027T3/da active
- 1993-04-07 WO PCT/GB1993/000732 patent/WO1993020816A1/en not_active Ceased
- 1993-04-07 DE DE69325574T patent/DE69325574T2/de not_active Expired - Fee Related
- 1993-04-07 AT AT93909041T patent/ATE181830T1/de not_active IP Right Cessation
- 1993-04-07 CA CA002132544A patent/CA2132544C/en not_active Expired - Fee Related
- 1993-04-07 JP JP5518094A patent/JPH07505646A/ja active Pending
- 1993-04-07 AU AU39589/93A patent/AU675935B2/en not_active Ceased
- 1993-04-07 HU HU9402932A patent/HUT71331A/hu not_active Application Discontinuation
-
1994
- 1994-10-11 KR KR19940703608A patent/KR100292396B1/ko not_active Expired - Fee Related
- 1994-10-12 NO NO19943846A patent/NO313935B1/no not_active IP Right Cessation
-
1999
- 1999-09-20 GR GR990402358T patent/GR3031261T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE181830T1 (de) | 1999-07-15 |
| DE69325574D1 (de) | 1999-08-12 |
| EP0636027B1 (en) | 1999-07-07 |
| AU3958993A (en) | 1993-11-18 |
| GR3031261T3 (en) | 1999-12-31 |
| NZ251741A (en) | 1997-06-24 |
| CA2132544C (en) | 2005-10-18 |
| DE69325574T2 (de) | 2000-03-16 |
| EP0636027A1 (en) | 1995-02-01 |
| DK0636027T3 (da) | 2000-01-31 |
| NO943846D0 (no) | 1994-10-12 |
| AU675935B2 (en) | 1997-02-27 |
| CA2132544A1 (en) | 1993-10-28 |
| HU9402932D0 (en) | 1995-02-28 |
| NO943846L (no) | 1994-10-12 |
| HUT71331A (en) | 1995-11-28 |
| KR100292396B1 (https=) | 2001-09-17 |
| ES2135472T3 (es) | 1999-11-01 |
| EP0872235A1 (en) | 1998-10-21 |
| JPH07505646A (ja) | 1995-06-22 |
| WO1993020816A1 (en) | 1993-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO313935B1 (no) | Anvendelse av angiotensin II antagonister for fremstilling av et medikamentfor behandling av svekket nerveledningshastighet, s¶rligdiabetisk nevropati | |
| TWI415599B (zh) | Ｐｄｅiii抑制劑用於降低罹患心臟衰竭之哺乳動物之心臟大小之用途 | |
| KR102860817B1 (ko) | 트라디피턴트에 의한 치료 방법 | |
| MXPA00002784A (es) | Sistema basado en modelo estadistco multivariado pra verificar la operacion de un fundidor continuo y detectar la aparicion de rebabas por rotura de molde inminentes. | |
| HU202108B (en) | Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol | |
| KR20180127493A (ko) | 승모판 질환으로 인한 무증상 심부전이 있는 환자에서 심장 크기의 감소 및/또는 임상적 증상 개시의 지연을 위한 피모벤단의 용도 | |
| WO1993004688A1 (en) | Pharmaceutical preparation containing an uricosuric and an excitatory amino acid antagonist | |
| EP2716302B1 (en) | Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome | |
| KR20120050473A (ko) | 탈수초성 질환 및 다른 신경계 질환을 앓는 환자에서 신경-인지 및/또는 신경-정신 손상을 개선하기 위한 4-아미노피리딘의 용도 | |
| JP2009539996A (ja) | 腎機能障害を持つ個体における利尿改善方法 | |
| EP3132803B1 (en) | Preventive or therapeutic agent for pain associated with herpes zoster in acute phase | |
| CN101420958A (zh) | 共投与腺苷a1受体拮抗剂和抗惊厥药 | |
| WO1997021439A1 (fr) | Medicament destine au traitement des troubles obsessifs compulsifs, de l'apnee du sommeil, des dysfonctions sexuelles, de l'emese et du mal des transports | |
| DE602004012763T2 (de) | Pharmazeutische zusammensetzung mit einem selektiven i1 imidazolin-rezeptor-agonisten und einem angiotensin-ii-rezeptorblocker | |
| ZA200509311B (en) | Method of improved diuresis in individuals with impaired renal function | |
| US6448280B1 (en) | Angiotensin II antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy | |
| KR100443891B1 (ko) | 당뇨병성합병증의예방·치료제 | |
| TWI289060B (en) | Pharmaceutical composition for improving the recovery of post-stroke patients | |
| EP2517728B1 (en) | Olmesartan medoxomil for preventing or treating angiogenic eye diseases | |
| DE69910600T2 (de) | Verwendung von metformin gegen die gewichtszunahme, die mit valproat und andere psychotropische arzneimittel verbunden ist | |
| MXPA06011823A (es) | Terapia de combinacion, que comprende un antagonista del receptor de la adenosina a1 y un inhibidor de la aldosterona. | |
| JPH0532635A (ja) | ヒスタミン誘導体の治療への応用と、新規なヒスタミン誘導体と、この誘導体の医薬としての使用 | |
| US4522820A (en) | Trans-dihydrolisuride antipsychotic | |
| JPH06211657A (ja) | 尿酸排泄剤 | |
| EP1932529A1 (en) | Method of improved diuresis in individuals with impaired renal function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |